Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2024 Sep;38(9):e15464.
doi: 10.1111/ctr.15464.

Hepatitis B Vaccine Compliance, Serologic Response, and Durability in Adult Thoracic Organ Transplant Recipients

Chia-Yu Chiu  1   2 , Priya Sampathkumar  1 , Lisa M Brumble  3 , Holenarasipur R Vikram  4 , Kymberly D Watt  5   6 , Elena Beam  1   6
Affiliations
Multicenter Study

Hepatitis B Vaccine Compliance, Serologic Response, and Durability in Adult Thoracic Organ Transplant Recipients

Chia-Yu Chiu et al. Clin Transplant. 2024 Sep.

Abstract

Introduction: Hepatitis B virus (HBV) vaccination is recommended for solid organ transplant (SOT) candidates. However, there is a lack of data on the HBV vaccine compliance, serologic response, and durability of HBV seroprotection in thoracic organ transplantation recipients.

Methods: We conducted a retrospective study of adult thoracic organ (heart and lung) transplant candidates who received HBV vaccination at Mayo Clinic sites in Minnesota, Arizona, and Florida between January 2018 and August 2023. Conventional recombinant hepatitis B vaccine (Recombivax HB) was used before 2020, and Heplisav-B was preferred after 2020. HBV seroprotection was defined as hepatitis B surface antibody (HBsAb) ≥ 10 IU/L. Furthermore, we compared characteristics between recipients who maintained HBV seroprotection and those who lost HBV seroprotection (HBsAb < 10 IU/L) at 30 days posttransplantation (D30).

Results: Among 922 candidates who were eligible for HBV vaccination, 430 (47%) completed the HBV vaccine series. Patients receiving Heplisav-B were more likely to complete the series than Recombivax HB (81% vs. 60%, p < 0.001) and Heplisav-B had a higher seroprotection rate than Recombivax HB (75% vs. 64%, p = 0.023). Multivariate logistic regression analysis identified receiving Heplisav-B as an independent predictor for HBV seroprotection (adjusted odds ratio [aOR] 1.723; 95% confidence interval [CI] 1.056-2.810; p = 0.029). A total of 145 thoracic organ transplant recipients achieved HBV seroprotection at the date of transplantation. Loss of HBV seroprotection occurred in 38 (26%) patients at D30. Multivariate logistic regression analysis identified two predictors for HBV seroprotection loss at D30: age ≥ 60 years (aOR, 2.503; 95% CI 1.026-6.107; p = 0.044), and pretransplant HBsAb level between 10 and 100 IU/L (aOR, 18.575; 95% CI 5.211-66.209; p < 0.001).

Conclusions: Although less than half of thoracic organ transplant candidates completed HBV vaccine series pretransplant, Heplisav-B provided a higher vaccine completion rate and seroprotection than the 3-dose Recombivax HB. Clinicians should also be aware of the increased loss of HBV seroprotection in thoracic organ transplant recipients with age ≥ 60 years and pretransplant HBsAb between 10 and 100 IU/L. Assessment of seroprotection after HBV vaccination should be prioritized during the pretransplant period.

Keywords: expanding the donor pool; heart transplant; hepatitis B virus; lung transplant; organ donation.

PubMed Disclaimer

References

    1. M. Malinis and H. W. Boucher, “Screening of Donor and Candidate Prior to Solid Organ Transplantation‐Guidelines From the American Society of Transplantation Infectious Diseases Community of Practice,” Clinical Transplantation 33, no. 9 (2019): e13548.
    1. L. Danziger‐Isakov and D. Kumar, “Vaccination of Solid Organ Transplant Candidates and Recipients: Guidelines From the American Society of Transplantation Infectious Diseases Community of Practice,” Clinical Transplantation 33, no. 9 (2019): e13563.
    1. S. Schillie, C. Vellozzi, A. Reingold, et al., “Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices,” MMWR Recommendations and Reports 67, no. 1 (2018): 1–31.
    1. D. Jandhyala and J. D. Lewis, “An Analysis of Adherence to Vaccination Recommendations in a Thoracic Organ Transplant Cohort,” Vaccines 8, no. 4 (2020): 622.
    1. Z. B. Harboe, A. Hald, C. Ekenberg, et al., “Implementation of a Vaccination Clinic for Adult Solid Organ Transplant Candidates: A Single‐center Experience,” Vaccine 41, no. 45 (2023): 6637–6644.

Publication types

Substances

LinkOut - more resources